Business Context and Reporting Period
This Form 8-K reports on the 2018 Annual Meeting of Stockholders held by MacroGenics, Inc. on May 17, 2018. The filing details the voting outcomes for three proposals submitted to security holders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
A total of 28,971,270 shares were present or represented by proxy, representing approximately 78% of the 37,022,921 outstanding shares entitled to vote. All three proposals were approved:
- Proposal 1 (Director Election): Three Class II director nominees were elected for three-year terms.
- Kenneth Galbraith: 26,046,765 For; 181,489 Withheld.
- Scott Jackson: 26,142,047 For; 86,207 Withheld.
- David Stump, M.D.: 26,046,618 For; 181,636 Withheld.
- Proposal 2 (Auditor Ratification): Ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2018.
- Results: 28,888,670 For; 78,598 Against; 4,002 Abstain.
- Proposal 3 (Executive Compensation): Advisory approval of named executive officer compensation.
- Results: 25,787,036 For; 432,673 Against; 8,545 Abstain; 2,743,016 Broker Non-Votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the definitive proxy statement filed on April 6, 2018, for detailed descriptions of the proposals.
- Confirm the record date of March 23, 2018, for share ownership eligibility.
- Note the significant number of broker non-votes (2,743,016) on the executive compensation advisory vote.
- Review the terms of the newly elected directors (Class II, three-year terms).